Holen Sie sich die Stockscreener-App
7.48
1.06%
-0.08
Handel nachbörslich:
7.45
-0.03
-0.40%
Schlusskurs vom Vortag:
$7.56
Offen:
$7.48
24-Stunden-Volumen:
1.58M
Relative Volume:
1.39
Marktkapitalisierung:
$596.55M
Einnahmen:
$116.30M
Nettoeinkommen (Verlust:
$17.73M
KGV:
35.62
EPS:
0.21
Netto-Cashflow:
$20.88M
1W Leistung:
+7.94%
1M Leistung:
-22.08%
6M Leistung:
+31.92%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.28
$7.69
1-Wochen-Bereich:
$6.995
$7.70
52-Wochen-Spanne:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie NAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
7.48 | 602.93M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
What earnings revisions data tells us about Niagen Bioscience Inc.2025 Market Overview & Expert Curated Trade Ideas - newser.com
Niagen Bioscience's (NAGE) Hold (C) Rating Reiterated at Weiss Ratings - MarketBeat
Tools to assess Niagen Bioscience Inc.’s risk profileJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Owning 37% shares,institutional owners seem interested in Niagen Bioscience, Inc. (NASDAQ:NAGE), - Yahoo Finance
What is Roth Capital’s Estimate for NAGE Q3 Earnings? - Defense World
When is the best time to exit Niagen Bioscience Inc.Global Markets & Risk Controlled Daily Plans - newser.com
Pattern recognition hints at Niagen Bioscience Inc. upsideJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Will Niagen Bioscience Inc. stock go up soonTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com
How Niagen Bioscience Inc. (OCD1) stock trades pre earningsJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
Full technical analysis of Niagen Bioscience Inc. stockShare Buyback & Capital Protection Trading Alerts - newser.com
Niagen Bioscience raises 2025 sales outlook on NAD+ market growth By Investing.com - Investing.com Nigeria
Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling - TipRanks
Niagen Bioscience, Inc. Provides Net Sales Guidance for the Full-Year 2025 - MarketScreener
Niagen Bioscience (NAGE) Gains Attention with FDA's NMN Ruling R - GuruFocus
Niagen Bioscience (NAGE) Boosts 2025 Sales Forecast - GuruFocus
Niagen Bioscience increases full year 2025 net sales outlook to 25% to 30% year-over-year growth - MarketScreener
Niagen Bioscience raises 2025 sales outlook on NAD+ market growth - Investing.com India
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth - Business Wire
What margin trends mean for Niagen Bioscience Inc. stockEarnings Beat & Technical Buy Zone Confirmation - newser.com
Is Niagen Bioscience Inc. reversing from oversold territoryJuly 2025 Selloffs & Trade Opportunity Analysis Reports - newser.com
Roth Capital Issues Pessimistic Estimate for NAGE Earnings - Defense World
A Fresh Look at Niagen Bioscience (NAGE) Valuation After Nationwide iCRYO Distribution Expansion - Sahm
Roth Capital Lowers Earnings Estimates for Niagen Bioscience - MarketBeat
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Retreats 25% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
What macro factors could drive Niagen Bioscience Inc. (OCD1) stock higher2025 Market WrapUp & Precise Buy Zone Identification - newser.com
Niagen Bioscience's Pharmaceutical-Grade Niagen IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - MarketScreener
Niagen IV now available at over 900 clinics nationwide By Investing.com - Investing.com Canada
Niagen Bioscience (NAGE) Expands Product Reach to Over 900 U.S. Clinics - GuruFocus
Niagen IV now available at over 900 clinics nationwide - Investing.com India
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - Yahoo Finance
Analyzing Niagen Bioscience (NASDAQ:NAGE) and CureVac (NASDAQ:CVAC) - Defense World
Niagen Bioscience (NASDAQ:NAGE) Trading Down 6.4%What's Next? - MarketBeat
Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Price Target at $13.42 - Defense World
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):